. Since 2002, there has been an alarming increase in S. flexneri resistant to fluoroquinolones in India, thereby limiting the treatment options [8] [9] [10] [11] . We report here two isolates of S. flexneri type 2a isolated from a hospital in Kerala in 2010 which were found to be resistant to fluoroquinolones and possessed mutations in gyrA and parC genes.
Two isolates of Shigella (SF1 and SF2) were isolated from a 62 yr old female and a 52 yr old male dysentery patients who presented with severe bleeding per rectum, fever and inflammatory bowel disease, admitted to Medical College Hospital, Thiruvananthapuram, Kerala, India in 2010. There was no history of travelling and they were taking protein powder as food supplement. Both patients responded well with injection of cefotaxime. The isolates were confirmed as Shigella species by biochemical tests and serotyped using commercially available antisera (Denka Seiken, Tokyo, Japan). These were stored in Luria-Bertani broth (BD, Difco, MD, USA) containing 50 per cent glycerol at -80°C.
Antibiotic susceptibility testing was performed using the Kirby-Bauer disc susceptibility method 12 according to Clinical Laboratory Standards Institute guidelines 13 . The antibiotic discs (µg) (Hi-Media Laboratories, Mumbai, India) used were ampicillin (10), ceftriaxone (30), nalidixic acid (30), ciprofloxacin (5), ofloxacin (5), norfloxacin (10), trimethoprim (5), tetracycline (30), chloramphenicol (30), streptomycin (10), gentamicin (10) and co-trimoxazole (1.25 + 23.75). Escherichia coli ATCC 25922 was used as control. The minimum inhibitory concentrations (MICs) of nalidixic acid, norfloxacin and ciprofloxacin were determined using E test (AB Biodisk, Solna, Sweden).
The bacterial cell lysate was used as a template for PCR analysis. The bacteria grown overnight at 37 °C in Luria-Bertani broth were boiled, snap-cooled and stored at -20°C until use. Quinolone resistance determining regions (QRDR) of gyrA, gyrB, parC and parE were amplified as described previously 14, 15 . The amplified products were separated on a 1 per cent agarose gel, stained with ethidium bromide and visualized using a BIORAD Gel Doc EZ Imager (Bio Rad, USA). PCR products were purified using ExosapIT (USB) and sequencing reactions were carried out using the Big Dye Terminator Cycle Sequencing kit (Applied Biosystems, USA). Nucleotide sequencing was performed in both directions with the same PCR primers used for the amplification of the target genes in an automatic sequencer (ABI Prism 3200; Applied Biosystems). Sequences were edited with BIOEDIT v7. The two Shigella isolates (SF1 and SF2) were identified as S. flexneri 2a by serotyping with specific antisera. Antibiogram revealed that both the isolates were resistant to ampicillin, co-trimoxazole, nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin, trimethoprim, chloramphenicol, streptomycin and gentamicin. The isolates did not show resistance to ceftriaxone. Antimicrobial resistance has been increasing among Shigella and the choice of antibiotics becoming limited with the emergence of multidrug resistant strains. In the present investigation, the test isolates were resistant to two or more classes of antibiotics, including ampicillin and co-trimoxazole. Similar findings have been reported from different parts of the country 8-10 . Both isolates showed high level resistance to ciprofloxacin (MICs of 24 and 12 µg/ml) and for norfloxacin (MICs of 32 µg/ml for both). Both isolates possessed mutations in gyrA at position 87 with the replacement of D-aspartic acid with N-asparagine and at position 80 of parC with the replacement of serine by isoleucine. None of the isolates had any mutation in gyrB or parE genes. The mutation reported in parC gene is in accordance with the previous reports 9, 15 . In gyrA gene, mutation initially happens at 83 rd position (S83L) followed by D87N 16 . But in the present study, the isolates did not show any change at 83 rd position of gyrA gene. The resistance to fluoroquinolones may be due to the acquisition of mutations in the QRDR of DNA gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE), plasmidmediated quinolone resistance (PMQR) determinants, such as (qnr), aminoglycoside aac(6′)-Ib-cr and active efflux of quinolones 17 . Since only the QRDR genes were sequenced, the possibility of other mechanisms in the observed resistance to fluoroquinolones was not ruled out.
Shigellosis is a major public health problem in India and several reports have identified S. flexneri to be the predominant circulating serotype in different parts of the country 8, 10, 11, 18, 19 . A study conducted in 1978 identified 16 shigellae from Calicut and Trivandrum, of which eight were S. flexneri. Three of these showed resistance to ampicillin, chloramphenicol, streptomycin, sulphadiazine and tetracycline 20 . The emergence of fluoroquinolone resistant S. flexneri type 2a is a therapeutic challenge in the treatment of shigellosis. Periodic monitoring and reporting of Shigella serotypes circulating in the country and their antibiotic susceptibility will help the clinicians in the proper selection of drugs and their judicious use for shigellosis.
